Mucoadhesive vaginal tablets as veterinary delivery system for the controlled release of an antimicrobial drug, acriflavine

被引:35
作者
Elisabetta Gavini
Vanna Sanna
Claudia Juliano
Maria Cristina Bonferoni
Paolo Giunchedi
机构
[1] Università di Sassari,Dipartimento di Scienze del Farmaco
[2] Università di Pavia,Dipartimento di Chimica Farmaceutica
关键词
Chitosan; acriflavine; veterinary dosage form; vaginal delivery systems; microspheres; mucoadhesive tablets;
D O I
10.1208/pt030320
中图分类号
学科分类号
摘要
The aim of the study was the development of mucoadhesive vaginal tablets designed for the local controlled release of acriflavine, an antimicrobial drug used as a model. The tablets were prepared using drug-loaded chitosan microspheres and additional excipients (methylcellulose, sodium alginate, sodium carboxymethylcellulose, or. Carbopol 974). The microspheres were prepared by a spray-drying method, using the drug to polymer weight ratios 1∶1 and 1∶2 and were characterized in terms of morphology, encapsulation efficiency, and in vitro release behavior, as MIC (Minimum Inhibitory Concentration), MBC (Minimum Bacterial Concentration), and killing time (KT). The tablets were prepared by direct compression, characterized by in vitro drug release and in vitro mucoadhesive tests. The microparticles have sizes of 4 to 12 μm; the mean encapsulation yields are about 90%. Acriflavine, encapsulated into the polymer, maintains its antibacterial activity; killing time of the encapsulated drug is similar to that of the free drug. In vitro release profiles of tablets show differences depending on the excipient used. In particular Carbopol 974, which is highly cross-linked, is able to determine a drug-controlled release from the matrix tablets for more than 8 hours. The in vitro adhesion tests, carried out on the same formulation, show a good adhesive behavior. The formulation containing microspheres with drug to polymer weight ratios of 1∶1 and Carbopol 974 is characterized by the best release behavior and shows good mucoadhesive properties. These preliminary data indicate that this formulation can be proposed as a mucoadhesive vaginal delivery system for the controlled release of acriflavine.
引用
收藏
相关论文
共 85 条
[1]  
Rothen-Weinhold R(2000)Formulation and technology aspects of controlled drug delivery in animals Pharm Sci Technol Today. 3 222-231
[2]  
Gurny MD(2000)The scope and potential of vaginal drug delivery Pharm Sci Technol Today. 3 359-364
[3]  
Vermani K(1994)Vaginal and reproductive system treatments using a bioadhesive polymer J Control Release. 28 87-94
[4]  
Garg S(1997)Spreading and retention of vaginal formulations in post-menopausal women as assessed by gamma scintigraphy Pharm Res. 28 1073-1078
[5]  
Robinson JR(2000)Bioadhesive-based dosage forms: the next generation J Pharm Sci. 89 850-866
[6]  
Bologna WJ(2002)Formulation and in vivo evaluation of chlorhexidine buccal tablets prepared using drug loaded chitosan microspheres Eur J Pharm & Biopharm. 52 233-239
[7]  
Brown J(1999)Polymeric films as vehicle for buccal delivery: swelling, mechanical, and bioadhesive properties J Pharm Sci. 2 53-61
[8]  
Hooper G(1999)Development and in vitro evaluation of buccoadhesive tablets using a new model substrate for bioadhesion measures: the eggshell membrane Drug Dev & Ind Pharm. 25 289-295
[9]  
Kenyon CJ(1999)Bioavailability of apomorphine following intranasal administration of mucoadhesive drug delivery systems in rabbits Eur J Pharm Sci. 9 213-219
[10]  
Haines S(2000)Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan J Control Release 66 281-292